Skip to main navigation Skip to search Skip to main content

A phase 2 study to evaluate the efficacy and safety of lorundrostat, a selective aldosterone synthase inhibitor alone, and in a combination with the sglt2 inhibitor dapagliflozin, in adults with chronic kidney disease

Project: Research

Project Details

StatusFinished
Effective start/end date10/15/23 → 12/31/25

Funding

  • Mineralys Therapeutics Limited Liability Corporation: $5,000.00